Needham & Company LLC Reaffirms “Buy” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Needham & Company LLC reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report released on Tuesday, Benzinga reports. The brokerage currently has a $205.00 price target on the specialty pharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. Robert W. Baird decreased their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an outperform rating on the stock in a report on Thursday, August 1st. JPMorgan Chase & Co. boosted their target price on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an overweight rating in a report on Monday, August 19th. StockNews.com upgraded shares of Jazz Pharmaceuticals from a buy rating to a strong-buy rating in a report on Thursday, August 1st. Royal Bank of Canada decreased their target price on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an outperform rating on the stock in a report on Thursday, August 1st. Finally, Cantor Fitzgerald restated an overweight rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Moderate Buy and a consensus target price of $173.07.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $108.79 on Tuesday. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. The firm has a market capitalization of $6.72 billion, a price-to-earnings ratio of 22.43, a PEG ratio of 1.31 and a beta of 0.57. The company’s 50-day moving average is $109.88 and its two-hundred day moving average is $111.71. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $137.38.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The transaction was disclosed in a document filed with the SEC, which is available through this link. 4.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of large investors have recently modified their holdings of JAZZ. Capital World Investors purchased a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $171,943,000. Swedbank AB purchased a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $106,936,000. Vestal Point Capital LP purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $89,175,000. Rubric Capital Management LP purchased a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $65,812,000. Finally, Pacer Advisors Inc. increased its position in shares of Jazz Pharmaceuticals by 40.7% in the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after purchasing an additional 527,187 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.